科兴制药跌2.09%，成交额2118.80万元，主力资金净流出42.11万元

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced a decline recently, despite a significant increase in its price year-to-date, indicating potential volatility in the market [1]. Financial Performance - As of June 30, Kexing Pharmaceutical reported a revenue of 700 million yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.34 million yuan, showing a substantial increase of 576.45% [2]. - Cumulatively, Kexing Pharmaceutical has distributed dividends amounting to 51.54 million yuan since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2]. - The top ten circulating shareholders include notable funds such as E Fund Healthcare Industry Mixed A and others, with significant increases in holdings for some [3].